HealthQuill Acquisition
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
Bain Capital, a US-based private investment company, will buy the pharmaceutical arm of the Mitsubishi Chemical Group Corp. for $3.3 billion, according to the Massachusetts-based firm.
Drugs Health Medical

Bain Capital to buy Japan’s Mitsubishi Tanabe Pharma for $3.3 billion

Bain Capital, a US-based private investment company, will buy the pharmaceutical arm of the Mitsubishi Chemical Group Corp. for $3.3 billion, according to.

Read More
Globus Medical, a US-based medical device company, will buy Nevro Corp. for $250 million in an all-cash deal.
Health Medical Pharma

Globus Medical Inc to buy US-based Nevro Corp for $250 million all cash

Globus Medical, a US-based medical device company, will buy Nevro Corp. for $250 million in an all-cash deal.

Read More
Zimmer Biomet Holdings, Inc., a US medical device maker, will acquire Paragon 28 Inc., for $1.1 billion to expand into musculoskeletal care, according to a company statement.
Health Medical Pharma

Zimmer Biomet to buy Paragon 28 for $1.1b to expand musculoskeletal care

Zimmer Biomet Holdings, Inc., a US medical device maker, will acquire Paragon 28 Inc., for $1.1 billion to expand into musculoskeletal care, according.

Read More
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from the Japanese company.
Drugs Health Pharma

Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million

Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.

Read More
Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to a J&J statement.
Drugs Medical Pharma

Johnson & Johnson to acquire Intra-Cellular Therapies Inc., for $14.6 billion

Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.

Read More
Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of 30%, according to a Securities and Exchange Commission filing.
Drugs Medical Pharma

Biogen Inc., to buy 62m outstanding shares of Sage for $441.7 million

Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of.

Read More
Eli Lilly and Company will invest $3 billion in the US to expand its manufacturing facility to meet a rise in demand for medicines in the areas of diabetes and obesity.
Uncategorized

Eli Lilly to expand US facility as demand soars for diabetes, obesity medicines

Eli Lilly and Company will invest $3 billion in the US to expand its manufacturing facility to meet a rise in demand for.

Read More
Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.
Drugs Health Pharma

Roche to acquire US-based Poseida Therapeutics for $1.5 billion

Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.

Read More
AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as Alzheimer’s disease, for $1.4 billion in cash.
Drugs Health Pharma

AbbVie to acquire Aliada for $1.4 billion, bags Alzheimer’s therapy 

AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as.

Read More